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Qifeng Li1, Ke Shen2, Yang Zhao1, Chenkai Ma1, Jianwen Liu2 and Jie Ma1*Abstract
Background: MiR-92b was upregulated in gliomas. However, the association of miR-92b with glioma cell apoptosis
and survival remains unknown.
Methods: Proliferation capability of glioma cells upon tranfection with miR-92b mimics or inhibitors was detected
by mutiple analyses, including MTT assays, colony formation assay. Apoptosis abilities of glioma cells were detected
by flow cytometric analysis. The target of miR-92b was determined by luciferase reporter and western blot. The
association of miR-92b with outcome was examined in twenty glioma patients.
Results: MiR-92b expression was significantly increased in high-grade gliomas compared with low-grade gliomas,
and positively correlated with the degree of glioma infiltration. Over-expression of miR-92b increased cell proliferation,
whereas knockdown of miR-92b decreased cell proliferation via modulating the levels of the target, Target prediction
analysis and a dual luciferase reporting assay confirmed that the inhibitory protein-coding Dickkopf-3 gene (DKK3)
was a direct target of miR-92b. Furthermore, miR-92b could regulate the expression of downstream genes of the
Wnt/beta-catenin signaling pathway, such as Bcl2, c-myc and p-c-Jun, in glioma cells. Finally, the increased level
of miR-92b expression in high-grade gliomas confers poorer overall survival.
Conclusions: The present data indicates that miR-92b directly regulate cell proliferation and apoptosis by targeting
DKK3 and act as prognostic factors for glioma patients.
Keywords: miR-92b, DKK3, The Wnt/beta-catenin signaling pathway, Glioma, PrognosisIntroduction
A glioma is the most common form of neural malignancy.
High grade glioma, especially glioblastoma, is a leading
cause of brain cancer fatality involving highly invasive
and neoplastic growth. Despite therapeutic advances,
many patients suffer from tumor recurrence due to
chemo- and radio- therapy resistance [1-3]. Increasing
evidence suggests that the progression of a glioma is
relative to the rate of both cell proliferation and apoptosis.
Therefore, understanding the main regulatory mechanism
of gliomas is key to the development of effective thera-
peutic approaches against this malignancy.* Correspondence: majie365@hotmail.com
1Department of Pediatric Neurosurgery, Xinhua Hospital, Shanghai Jiaotong
University, School of Medicine, Shanghai 200092, P R China
Full list of author information is available at the end of the article
© 2013 Li et al.; licensee BioMed Central Ltd. T
Commons Attribution License (http://creativec
reproduction in any medium, provided the orMicroRNAs (miRNAs) are small, endogenous, non-coding
RNA molecules, which usually result in gene silencing
by binding to complementary sequences in the three
prime untranslated regions (3-UTRs) of target messenger
RNA transcripts (mRNAs) [4-9]. The deregulation of
miRNAs has been observed in various types of human
malignancies, including lymphoma, colorectal cancer, lung
cancer, breast cancer, papillary thyroid carcinoma, hepato-
cellular carcinoma and glioblastoma [10-13]. Accounting
for approximately 1% of all the expressed human genes,
miRNAs are predicted to regulate the expression of up to
1/3 of human protein-coding genes [14-17]. A few studies
suggest that the downregulation of miRNAs may play a
critical role in cancer progression by affecting not only
proliferation but also apoptosis [18-20]. Primary brain
tumors expressed higher levels of miR-92b than both
primary tumors in other tissues and their metastases tohis is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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to modulate the expression of the inhibitory protein-coding
Dickkopf-3 gene (DKK3)[22]. However, the underlying
mechanism of mir-92b in gliomas has not been identified
so far.
In the current study, we demonstrate that high levels of
miR-92b expression in gliomas confer highly aggressive
invasion and poorer overall survival. Knockdown of
miR-92b decreased glioma cell prolifirelation, reduced
apoptosis and up-regulated the expression of the target,
DKK3, whereas ectopic expression of miR-92b exhibited
the opposite effects. Furthermore, miR-92b could regulate
the expression of downstream genes of the Wnt/beta-
catenin signaling pathway, such as Bcl2, c-myc and p-c-
Jun. These findings indicate that DKK3 is a critical target
of miR-92b and that the microRNA could be critical
therapeutic targets and survival predictors in glioma.
Materials and methods
The human glioma tissue samples and their corresponding
nontumorous tissues were collected at the time of surgical
resection at the Department of Pediatric Neurosurgery,
Xinhua Hospital, Shanghai Jiao Tong University. Twenty
frozen glioma specimens with clinical data were collected
from January 2008 to June 2013, including 9 grade I-II
tumors, 8 grade III tumors and 3 grade IV tumors. The
glioma samples were deep-frozen using liquid nitrogen,
stored at −80°C and were quantified by Real-time PCR.
This study was approved by the Institutional Review
Board of Xinhua hospital. Patients were followed by clinical
and laboratory monitoring on a regular basis starting at
definitive diagnosis. Disease-specific survival time was
defined as the time from definitive diagnosis to disease-
specific death.
Reagents
The antibodies aganist c-jun, phospho-c-jun, JNK, phospho-
JNK, DKK3, beta-catenin, Bcl-2, β-actin, caspase-3, Bax,
c-myc were purchased from Santa Cruz Biotechnology
(California, USA). The dual luciferase reporter assay
system, the PGL3-Promoter, the PGL3-Basic and PRL-
TK vectors were purchased from Promega (Promega
Corporation, Wisconsin, USA). The miRNA mimics and
siRNA were purchased from Biomics Biotechnologies
(Nantong, China). All other chemicals were from Sigma-
Aldrich unless otherwise stated.
Cell cultures and transfection
The human glioma cell lines U251, U87, A172 and SHG44,
and human astrocytes (HA) (Cell Bank of the Chinese
Academy of Science, Shanghai, China), were maintained
in RPMI 1640 medium (Gibco Industries, Inc. Carlsbad,
CA) with 10% fetal bovine serum (Gibco Industries, Inc.)
at 37°C in a humid atmosphere wih 5% CO2. Celltransfection was performed using Lipofectamine 2000
(Invitrogen) according to the manufacturer’s instructions.
MicroRNA microarrays
Total RNA was extracted from eight glioma tissues using
the miRVana miRNA Isolation Kit (Ambion, Carlsbad,
USA) according to the manufacturer’s instructions.
The samples were subsequently submitted to Shanghai
Biotechnology Corporation (Shanghai, China) for array
hybridization on an Agilent Human miRNA array (v.12.0).
Each microarray chip was hybridized with a single sample
labeled with either Cy3 or Cy5. Background subtraction
and normalization were performed. The raw data were de-
posited at Shanghai Biotechnology Corporation (Shanghai,
China) and have not been reported publicly up till the
present moment. We selected the miRNAs that exhibited
a difference in expression levels of at least 2-fold (p<0.05)
between the glioma tissue samples and their correspond-
ing nontumorous tissues.
RNA extraction and quantification
Total RNA was extracted using Trizol (Invitrogen
Corporation, California, USA) according to the manufac-
turer’s instructions. Reverse transcription was performed
using One Step PrimeScript®miRNA cDNA Synthesis
Kit (Takara Bio Inc, Dalian, China). Real-time PCR was
performed using SYBR®Premix Ex TaqTM II (Takara
Bio Inc, Dalian, China) with an iCycler®thermal cycler
(Bio-Rad, Hercules, USA).U6 RNA was used as a miRNA
internal control. The primers of miR-92b was as follows:
5′-TATTGCACTCGTCCCGGCCT-3′.
Colony formation assay
U251 and U87 cells were transfected with miR-92b mimics,
a control oligonucleotide and a miR-92b inhibitor. After
the transfection, the U251 and U87 cells were counted
and seeded in 12-well plates (in triplicates) at a density of
50 and 60 cells per well, respectively. The culture medium
was replaced every 3 days. The number of colonies was
counted on the sixth day after seeding. The rate of colony
formation was calculated with the following equation:
colony formation rate (%) = (number of colonies number
of seeded cells) × 100%.
MTT assays
The MTT assay was used to determine cell viability. All
the cells were seeded into 96-well culture plates (2×103
cells/well) in regular growth medium. The cells transfected
with miR-92b mimics. control and inhibitors were grown
for 4 days. One plate was developed immediately after the
medium change and other plates were developed every 24
hours for 4 days. Assays were initiated by adding 20 L of
MTT substrate to each well and incubating the cells for an
additional 3 hours. Finally, the medium was removed and
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measured at 492 nm using an Automated Microplate
Reader (Multiskan Ex, Lab systems, FIN).
RT-PCR
Analysis was used to determine the relative expression
levels of miRNAs. Total RNA was isolated using TRI-
ZOLTM reagent (Promega Corporation, Wisconsin, USA)
according to the supplier’s instruction. Reverse transcrip-
tion was done using One Step PrimeScript® miRNA cDNA
Synthesis Kit (TaKaRa Biotechnology Ltd, Shandong, CHN).
Real-time PCR was performed using SYBR Green Supermix
with an iCycler®thermal cycler (Bio-Rad Laboratories
Inc, California, USA).Primers of all genes were in Supple-
mentary. The data were collected and analyzed using the
comparative Ct (threshold cycle) method using GADPH
as the reference gene.
MicroRNA target prediction
The target genes of miR-92b were predicted by the fol-
lowing computer-aided algorithms: TargetScan Human
Release 6.2 (http://www.targetscan.org).
Luciferase assay
The 3′UTR of human DKK3, containing the putative target
sites for miR-92b, was amplified by PCR. The wild-type and
mutant inserts were transfected into the PGL3-promoter
vector. Dual-Luciferase reporter assays were performed
according to the manufacturer’s instructions (Promega,
Madison, WI) as previously described [23].
Flow cytometric analysis of apoptosis
Cells (6 *104/well) were plated in 6-well plates in antibiotic-
free medium and transfected with control oligonucleotide
(100 nM) or inhibitor (100 nM) using Lipofectamine 2000
(Invitrogen 4 Corporation, California, USA) according to
the manufacturer’s recommendation. Luciferase and renilla
signals were measured 48 h after transfection using the
Annexin V-FITC apoptosis detection kit (Invitrogen
Corporation, California, USA) as described by the manufac-
turer’s instructions. Three independent experiments were
performed and the data are presented as the mean + SD.
Western blot analysis
Total cell lysates (50 ug) were fractionated by SDS/PAGE.
The proteins were electroblotted onto nitrocellulose mem-
branes and Western blot analyses were carried out ac-
cording to standard procedures as previously described
[24]. β-actin was used as the loading control in the
Western blots.
Statistical analysis
The statistical analyses were performed using the Statistical
Package for the Social Sciences software using thetwo-tailed Student’s t-test. The significance was determined
at the 95% confidence interval. All the data were expressed
as the mean ± standard deviation (SD) from a representa-
tive experiment.Results
Expression and clinical significance of miR-92b in gliomas
To identify the miRNAs that are potentially involved in
gliomas, we first examined the miRNA expression profiles
in 8 glioma tissues and their corresponding nontumorous
tissues using Agilent Human miRNA array (v.12.0), which
consists of 873 capture probes for mature human miR-
NAs. After the microRNA expression was normalized by
U6 expression, The microarray results showed that 20
miRNAs were significantly overexpressed (fold change > 2,
p<0.05) in the glioma tissues (T) compared with their
corresponding normal tissues (N). On the other hand, 20
miRNAs were underexpressed significantly (fold change > 2,
p<0.05) (Figure 1A), The data have not been reported
publicly up till the present moment. Because the down-
regulated miRNAs have been studied by our colleagues,
we chose the upregulated miRNAs for further study. At
present, gliomas are classified as four grades from grade I
to grade IV. Gliomas with grade I and grade II are classi-
fied as low grade gliomas, whereas gliomas with grade III
and IV are classified as high grade gliomas. Generally,
comparing with high grade gliomas, low grade gliomas
have good results, because low grade gliomas have less
invasiveness. In our experiments, we performed real-time
PCR for quantitative analysis of miR-92b in 20 glioma
tissues. MiR-92b expression was significantly increased in
high-grade gliomas compared with low-grade gliomas,
and a similar trend for miR-92b was detected (Figure 1B).
We also analyzed the overall survival of 20 patients. The
Kaplan-Meier curves for patient according to miR-92b
expression levels in the glioma tissues are shown in
Figure 1C. The increased expression of miR-92b was
significantly associated with a poor overall survival
(p=0.030).A miR-92b Inhibitor Impeded Cell Viability and Colony
Formation and Promoted Apoptosis
To confirm miR-92b overexpression in glioma, we quan-
titated the expression of miR-92b in four glioma cell
lines, U251, U87, SHG44 and A172, and in a human
astrocyte cell line (HA). The results showed that miR-
92b expression was significantly higher in the glioma cells
than in the human astrocyte cell line (HA) (Figure 2A).
And the U251 and U87 glioma cell lines, which possessed
the highest levels of miR-92b expression among all tested
glioma cell lines, were selected for further studies. Because
the miR-92b expression was higher in the gliomas than in
the corresponding nontumorous tissues, we hypothesized
Figure 1 Expression and clinical significance of miR-92b in gliomas. (A) A heat map diagram generated by unsupervised clustering analysis
with 40 significantly deregulated miRNAs in eight human glioma tissues. The hierarchical clustering was performed with the average linkage and
uncentered correlation. The miRNA expression profile effectively segregated the human glioma samples from their corresponding nontumorous
tissues (frozen samples) (p<0.01). The red and green colors represent the high and low expression, respectively. (B) miR-92b expression in 20
glioma tissues assayed by real-time PCR. (C) Kaplan-Meier survival curves for miR-92b expression. High-grade glioma patients with high levels of
miR-92b had a significantly worse outcome. The expression level was categorized as low expression (final score 3) and high expression (>3).
The number of patients in each group was shown: miR-92b, low expression (9 patients) and high expression (11 patients).
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apoptosis and impede proliferation. Two glioma cell lines,
U251 and U87, were transfected with either miR-92b
mimics, a control oligonucleotide or a miR-92b inhibitor
(antisense oligonucleotide-miR-92b) to assess the effect
of miR-92b in glioma cells. The miR-92b inhibitor im-
peded colony formation, compared to the miR-92b mimics
(Figure 2B). Then, we performed an MTT assay and found
that the miR-92b inhibitor could reduce the viability of
the glioma cells significantly (p<0.001), whereas the
miR-92b mimics could promote their viability (p<0.05)(Figure 2C). Because the miR-92b inhibitor could impede
cell viability, we were interested in finding out whether it
could promote apoptosis. We used the Annexin V-FITC
analysis to assess the rate of apoptosis. In the U251 cells,
the miR-92b inhibitor caused apoptosis (45.2%), compared
to the control group (30.8%). In the U87 cells, the apop-
tosis rate was 55.9% with the miR-92b inhibitor, compared
to the control group (20.8%) (Figure 2D). The bar chart
represents our repeating results. All data were presented
as means ± SD and as representative of an average of three
measurements.
Figure 2 The effects of miR-92b on proliferation and apoptosis in U251 and U87 cells. (A) Realtime PCR analysis of miR-92b expression in
human astrocyte cell line (HA) and glioma cell lines (including U251, U87, SHG44 and A172). The average miR-92b expression was normalized by
U6 expression. Each bar represents the mean of three independent experiments. ***p<0.001. (B) After transfection, U251 and U87 cells were counted
and seeded separately in 12-well plates. The colonies were counted on the sixth day after seeding and the rate of colony formation was calculated. All
the data were representative of three independent experiments. (C) The rates of cell growth were measured using an MTT assay. All the cells were
seeded into 96-well culture plates. The absorbance at 492 nm was measured. MiR-92b mimics increased cell viability (**p<0.01). Conversely, miR-92b
inhibitors showed a significant decrease in cell viability (***p<0.001). All the data were presented as the mean ± SD of a representative average of three
independent experiments. (D) Three days after the transfection, the apoptosis was assessed using Annexin V-FITC analysis. Compared to the control
oligonucleotide group, a significant increase in cellular apoptosis was inducted by miR-92b inhibitors, whereas the miR-92b mimics group showed a
decrease in cellular apoptosis. The bar chart represents our repeating results. All data were presented as means ± SD and as representative of an
average of three measurements.
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To assess how the miR-92b inhibitor contributed to the
apoptosis in glioma cells, we investigated the potentialgene targets of miR-92b with the help of the prediction
tool TargetScanHuman Release 6.2. Hundreds of differ-
ent targets were predicted and the genes involved in
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potential relevant targets of miR-92b. One of these
genes, DKK3 (Figure 3A), is regarded as a secreted
antagonist of the Wnt/beta-catenin signaling pathway
[25,26]. Because this pathway is always activated in
gliomas [27-29], we hypothesized that the miR-92b
inhibitor could play a pro-apoptotic role by inhibiting
the Wnt/beta-catenin signaling pathway.
To test our hypothesis, we analyzed the protein levels
of DKK3 and miR-92b in the glioma cells. The results
showed a negative correlation between the levels of
miR-92b and DKK3 in the glioma cells (Figure 3B). We
then decided to test whether DKK3 is a direct target of
miR-92b. We first constructed a luciferase reporter in
which the nucleotides of the DKK3-3′UTR comple-
mentary to miR-92b were inserted into the 3′UTR of
PGL3-promoter vector (DKK3-WT). Correspondingly, we
also generated both a mutant reporter (DKK3-Mut), in
which the sequence in the miR-92b seed region comple-
mentary sites was changed (the sequence of the mutated
construct is 5′…AGGCUGUGGGUAGAUGCTGAAUA…),
and a control reporter (DKK3-Ctrl), which contained a
non-related fragment of cDNA. MiR-92b over-expressionFigure 3 DKK3 is a direct target of miR-92b. (A) The putative miR-92b-t
site to be in the 3′-UTR of DKK3. (B) The DKK3 protein level was assessed 48 h
(100 nM), the control oligonucleotide (100 nM) or the miR-92b inhibitor (100
protein was assayed as a control. Scanning densitometry of the blots was use
***p<0.001 t-test). All the data were presented as a representative average of
vector containing the DKK3 3'-UTR fragment with the miR-92b binding se
No luciferase activity change was observed when the cells were transfect
miR-92b binding sites. Each bar represents the mean of three independeplasmid was co-transfected with DKK3-WT or DKK3-
Mut or DKK3-Ctrl into cells. The assays showed that
the luciferase activity in the DKK3-WT transfected cells
significantly decreased compared to the luciferase activity
in the mutant and negative control cells and vice verse,
suggesting that miR-92b reduced the luciferase activity of
DKK3-WT but had no effect on DKK3-Mut (Figure 3C).
Therefore, we concluded that the DKK3 is the target of
miR-92b.
MiR-92b inhibitor impeded the Wnt/beta-catenin
signaling pathway by targeting DKK3
Because DKK3 is a critical antagonist of the Wnt/beta-
catenin signaling pathway, and miR-92b could inhibit
the expression of DKK3, we hypothesized that miR-92b
could modulate the Wnt/beta-catenin signaling pathway
via beta-catenin. To determine this, beta-catenin protein
levels were evaluated by Western blotting in cells treated
with either the miR-92b mimics, the control oligonucleo-
tide or the miR-92b inhibitor. The data showed that the
miR-92b mimics significantly promoted the expression
of beta-catenin, whereas the miR-92b inhibitor inhibited
the expression of beta-catenin (p<0.001) (Figure 4A).argeted sequence in the DKK3 gene. TargetScan predicts the binding
after transfection of U251 and U87 cells with either the miR-92b mimics
nM). DKK3 protein levels were detected by western blot assays. β-actin
d to quantify the Western blotting data. (n=3; means ± SEM **p<0.01,
three independent experiments. (C) The U87 cells transfected with the
quence had inhibited luciferase activity after miR-92b transfection.
ed with the plasmid containing a DKK3 3′-UTR fragment without the
nt experiments. ***p<0.001.
Figure 4 The alternation of the Wnt/beta-catenin signal pathway. The U251 and U87 cells were transfected with either the miR-92b mimics
(100 nM), the control oligonucleotide (100 nM) or the miR-92b inhibitor (100 nM). (A) The beta-catenin protein levels were assessed 48 h after
the transfection. β-actin was used as the loading control. The Western blots are representative of three independent experiments. Scanning
densitometry analysis of the blots was used to quantify the data. (B) Bcl2, c-myc, c-Jun (total and phosphorylated), Caspase-3 and Bax protein
levels were assessed 48 h after transfection with either the miR-92b mimics, the control oligonucleotide and the miR-92b inhibitor. β-actin
was used as the loading control. Scanning densitometry analysis of the blots was used to quantify the data. The data were expressed as the
mean ± SD and were representative of an average of three independent experiments. Significant differences from the control were indicated by
**p <0.01 and ***p <0.001.
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stream genes Bcl2, c-myc, c-Jun, phospho-c-Jun and the
pro-apoptotic genes Caspase-3 and Bax by Western
blotting. The results showed that the miR-92b inhibitor
could modulate the expression of these genes and that it
reduced the expression of Bcl2 greatly. Bcl-2 is not only a
downstream gene of the Wnt/beta-catenin signaling path-
way but also an anti-apoptotic gene. To test how miR-92b
stimulated apoptosis, we also analyzed the apoptotic
genes including Caspase-3 and Bax. The results showed
that Caspase-3 was activated in the cells treated with the
miR-92b inhibitor (Figure 4B).
Discussion
MicroRNAs play a crucial role in the process of tumor
formation. They impact the dynamic balance between
oncogenes and tumor suppressor genes by degrading
target genes, thereby contributing to cancer progression
[30]. Previous studies have shown that miR-92b is over-
expressed in brain primary tumor, as compared to primary
tumors from other tissues and their metastases to the
brain [21]. Based on topological and functional analyses, it
was also reported that miR-92b could play important roles
related to the Notch signaling pathway in Glioblastoma
multiforme (GBM) tumors [31]. However, there were no
reports about the association of miR-92b and survival.
In our study, we focused on the regulatory mechanisms
of the miR-92b in gliomas. Initially, the miRNA array
results showed that miR-92b was upregulated in gliomas,
which suggested that miR-92b could play an important
role in the development of gliomas as an oncogene. Thus,
we hypothesized that the downregulation of miR-92b
could promote apoptosis, providing a potential strategy
for glioma treatment. In vitro, our studies demonstrated
that the miR-92b inhibitor significantly promoted apop-
tosis and impeded cell viability and colony formation. To
determine how miR-92b was involved in the development
of gliomas, we used TargetScan and predicted that DKK3
was a probable target of miR-92b in the 3!UTR of DKK3.
We proved that the miR-92b overexpression resulted in
the downregulation of DKK3 at the protein level, whereas
the functional inhibition of miR-92b led to the inhibition
of DKK3, strongly suggesting that DKK3 is regulated by
miR-92b in gliomas. Meanwhile, a dual luciferase reporter
assay identified DKK3 as a direct target of miR-92b.
DKK3 is a critical antagonist of the Wnt/beta-catenin
signaling pathway [32], which has been shown to be
inhibited by miR-92b in neuroblastomas, but the mech-
anism in gliomas has not been elucidated fully [22]. A
previous study showed that the Wnt/beta-catenin signaling
pathway was activated in gliomas [33]. Thus, we speculated
that miR-92b played its role by regulating the Wnt/
beta-catenin signaling pathway. To elucidate the mechan-
ism, we detected the protein level of beta-catenin and thedownstream genes of the Wnt/beta-catenin signaling path-
way, such as Bcl2, c-myc, c-Jun and p-c-Jun. The results
showed that the overexpression of miR-92b inhibited
DKK3 and increased the expression of beta-catenin
(Figure 4A), which suggested that miR-92b modulated
beta-catenin via DKK3. To verify whether miR-92b could
modulate the Wnt/beta-catenin signaling pathway, we
measured the expression of the downstream genes
Bcl2, c-myc, c-Jun and p-c-Jun by Western blotting.
The results showed that the miR-92b inhibitor could
modulate the expression of these genes. The protein
expression of Bcl-2, which is not only a downstream
gene of the Wnt/beta-catenin signaling pathway but is
also an anti-apoptotic gene, was inhibited by miR-92b.
This demonstrated that miR-92b could modulate the
genes downstream of the Wnt/beta-catenin signaling
pathway. Furthermore, it could modulate apoptosis. To
testify how miR-92b affected apoptosis, we analyzed the
apoptotic genes Caspase-3 and Bax. The results demon-
strated that miR-92b increased the expression of Caspase-3
and Bax, indicating that Caspase-3 was activated after
treatment with the miR-92b inhibitor (Figure 4B).
Recent data showed miR-92b could regulate Wnt/beta-
catenin signaling via Nemo-like kinase [34]. However, the
significance of miR-92b in prognostic determination have
not been shown in glioma. In this study, our data suggest
that a high miR-92b expression level might be a valuable
marker for pathological diagnosis and prognosis predic-
tion in high-grade glioma; high miR-92b expression levels
were significantly associated with poor survival in high-
grade glioma patients as determined by Kaplan-Meier
analysis.
In summary, our data demonstrated that the miR-92b
could regulated glioma cell proliferation, apoptosis by
directly targeting DKK3. We also provide direct evidence
that high levels of miR-92b expression are significantly
associated with poorer overall survival. To conclude, our
data suggest that miR-92b could be a intrinsic regulator
of progression in glioma cells and could function as a
potential target and predictor of survival in glioma.
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